Spots Global Cancer Trial Database for secondary central nervous system lymphoma
Every month we try and update this database with for secondary central nervous system lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | NCT04457869 | Primary Central... Secondary Centr... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | NCT03964090 | Central Nervous... Secondary Centr... | TEDD-R TEDDI-R Ibrutinib Cytarabine Isavuconazole Methotrexate | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | NCT05256641 | Diffuse Large B... High-grade B-ce... Transformed Lym... Secondary Centr... | Acalabrutinib | 18 Years - 70 Years | Jonsson Comprehensive Cancer Center | |
| A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | NCT05485753 | Primary Central... Secondary Centr... | GNC-038 | 18 Years - | Sichuan Baili Pharmaceutical Co., Ltd. | |
| A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | NCT04438044 | PCNSL Secondary Centr... | ICP-022 | 18 Years - 75 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | NCT04457869 | Primary Central... Secondary Centr... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | NCT04457869 | Primary Central... Secondary Centr... | F520 | 18 Years - | Shandong New Time Pharmaceutical Co., LTD | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| R-MTX-zanbrutinib in Secondary CNS Lymphoma | NCT05398224 | Secondary Centr... | Zanubrutinib, h... | 18 Years - 75 Years | Peking University | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | NCT04438044 | PCNSL Secondary Centr... | ICP-022 | 18 Years - 75 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | NCT05011045 | Central Nervous... Hematopoietic a... Leukemia Lymphoma Plasma Cell Mye... Secondary Centr... | Magnetic Resona... Neurocognitive ... Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | NCT03964090 | Central Nervous... Secondary Centr... | TEDD-R TEDDI-R Ibrutinib Cytarabine Isavuconazole Methotrexate | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
